Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program

• Main Authors: T. O. Bessonova (Author), P. A. Mukhortova (Author), R. A. Teryan (Author), A. D. Bagdasarov (Author), N. Z. Musina (Author)
• Format: Bog
• Udgivet: IRBIS LLC, 2023-04-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

Objective: to evaluate the clinical and economic feasibility of expanding the preferential drug provision (PDP) program for adult patients at very high cardiovascular (CV) risk, including those who have not reached lipid targets on statin therapy, by increasing the frequency of use of ezetimibe, ali...